Bivalent Bcl-2 Inhibitors with Conditional Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Bcl-2 inhibitors, such as venetoclax, face challenges with on-target platelet toxicity, limiting their therapeutic potential due to Bcl-xL inhibition, and many cancer patients develop resistance, necessitating a strategy to retain antitumor efficacy while minimizing platelet toxicity.
Innovation Solution
Development of bivalent compounds that connect a Bcl-2 small molecule inhibitor to an E3 ligase binding moiety, like CRBN or VHL, to selectively degrade anti-apoptotic Bcl-2 proteins, thereby reducing platelet toxicity by targeting Bcl-xL in cancer cells with minimal expression in platelets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Bcl-2 inhibitors are used to treat cancer, then anticancer activity is improved, but platelet toxicity increases
Solution Approach 1:
The invention divides the Bcl-2 inhibitor into two separate functional components: a Bcl-2 binding domain and a Bcl-xL binding domain. This segmentation allows selective targeting of Bcl-2 in cancer cells while avoiding Bcl-xL inhibition in platelets, thereby maintaining anticancer activity while reducing platelet toxicity
Solution Approach 2:
The invention introduces a conditional linker as an intermediary element that connects the Bcl-2 and Bcl-xL binding domains. This linker acts as a mediator that is stable in circulation but cleaved intracellularly, enabling selective Bcl-2 inhibition in cancer cells while the Bcl-xL binding domain remains sequestered until activation
2Object-affected harmful factors
If selective Bcl-2 inhibition is achieved to reduce platelet toxicity, then platelet toxicity is reduced, but many patients develop resistance
Solution Approach 1:
The invention merges two functional domains (Bcl-2 binding and Bcl-xL binding) into a single bifunctional molecule. This combination ensures that while Bcl-2 is selectively inhibited in cancer cells, the Bcl-xL binding domain provides backup activity to overcome resistance mechanisms that may upregulate Bcl-xL in response to Bcl-2 inhibition
Solution Approach 2:
The invention introduces conditional activation dynamics where the inhibitor transitions from an inactive circulating form to an active intracellular form. This dynamic behavior allows the drug to adapt to different cellular environments, maintaining efficacy even when cancer cells develop resistance through Bcl-xL upregulation
3Reliability
If Bcl-xL inhibitors are used to overcome resistance, then antitumor efficacy is improved, but on-target platelet toxicity increases
Solution Approach 1:
The invention applies local quality by making the Bcl-xL binding domain conditionally active only in the intracellular environment of cancer cells. The conditional linker ensures that Bcl-xL inhibition occurs locally within cancer cells where resistance may develop, while platelets expressing Bcl-xL on their surface are spared from toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds achieve reduced platelet toxicity and enhanced anticancer activity, with a higher ratio of human platelet toxicity IC50 to anticancer activity IC50, effectively targeting Bcl-2-mediated cancers like chronic lymphocytic leukemia with improved therapeutic index.
Implementation Method 1
connect a Bcl-2 small molecule inhibitor to an E3 ligase binding moiety, like CRBN or VHL, to selectively degrade anti-apoptotic Bcl-2 proteins
Data Source
AI summary
The invention is directed towards compounds (e.g., Formula (I)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formula (I)).